-+ 0.00%
-+ 0.00%
-+ 0.00%

*Johnson & Johnson: In 3Q, Advanced Breakthroughs That Will Redefine Care for Patients, From Delivering One of Our Most Transformative MedTech Innovations With Ottava to Reporting Positive Phase 3 Results in Multiple Myeloma >JNJ

Dow Jones·10/13/2026 10:20:00

Please log in to view news